Evaluation of C. cassia Effectiveness in Behavioral Modulation of Haloperidol Induced Parkinson’s Disease (Mice Model)

Zaidi, Awais Ali; Khan, Tanveer A.; Shakir, Lubna; Khan, Mahtab Ahmad; Yousaf, Muhammad; Ali, Arsalan; Saeed, Atif; Zaka-Ur-Rehman,

doi:10.9734/bjpr/2016/29286

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have found an increase in TOS and a decrease in TAS in plasma in patients at risk, which is consistent with the results of previous data obtained from patients with diagnosed PD [79,80]. Moreover, our data on changes in ASI in patients at risk of developing PD correlate with our data on changes in the plasma concentration of urates, which are powerful antioxidants [81][82][83][84]. In fact, an increase in OSI in patients at risk of developing PD is accompanied by a decrease in plasma urate concentration.…”

Section: Plasma Oxidative Stress Index In Patients At Risk Of Develop...supporting

confidence: 92%

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

Katunina

Блохин

Nodel

et al. 2023

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD) is diagnosed many years after its onset, under a significant degradation of the nigrostriatal dopaminergic system, responsible for the regulation of motor function. This explains the low effectiveness of the treatment of patients. Therefore, one of the highest priorities in neurology is the development of the early (preclinical) diagnosis of PD. The aim of this study was to search for changes in the blood of patients at risk of developing PD, which are considered potential diagnostic biomarkers. Out of 1835 patients, 26 patients were included in the risk group and 20 patients in the control group. The primary criteria for inclusion in a risk group were the impairment of sleep behavior disorder and sense of smell, and the secondary criteria were neurological and mental disorders. In patients at risk and in controls, the composition of plasma and the expression of genes of interest in lymphocytes were assessed by 27 indicators. The main changes that we found in plasma include a decrease in the concentrations of l-3,4-dihydroxyphenylalanine (L-DOPA) and urates, as well as the expressions of some types of microRNA, and an increase in the total oxidative status. In turn, in the lymphocytes of patients at risk, an increase in the expression of the DA D3 receptor gene and the lymphocyte activation gene 3 (LAG3), as well as a decrease in the expression of the Protein deglycase DJ-1 gene (PARK7), were observed. The blood changes we found in patients at risk are considered candidates for diagnostic biomarkers at the prodromal stage of PD.

show abstract

Section: Plasma Oxidative Stress Index In Patients At Risk Of Develop...supporting

confidence: 92%

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

Katunina

Блохин

Nodel

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Group C and D were administered Pyridine-3-carboxylic acid orally, 7.15 mg and 15 mg per kg of body weight orally for 36 days respectively. (Zaidi et al, 2016a).…”

Section: Phase-iimentioning

confidence: 99%

“…The incidence of Parkinson's disease (PD) is nearly about 1% at the age of 65 years which further increased to 5% with the age of 85 years (Hirtz et al, 2007). Haloperidol is a typical neuroleptic drug and shows effect by blocking the postsynaptic dopamine D 2 receptors in the mesolimbic system and cause an escalation of dopamine turnover by blockage of the D 2 receptors (Zaidi et al, 2016a). Anticholinergic and β-adrenergic receptor blocking effects of haloperidol is quite weak.…”

Section: Introductionmentioning

confidence: 99%

“…Haloperidol causes a decrease in dopamine neurotransmission (Naidu et al, 2003). Haloperidol exerts its antipsychotic effect most likely through potent blockade of central dopamine receptors and marked rigidity linked with haloperidol administration (Zaidi et al, 2016b). In animal studies, neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) and 6-OHDA and haloperidol are used commonly to create experimental model of PD (Fernagut et al, 2002;Sheidaei, 2010) by which certain aspects of the disease such as motor abnormalities and slowing and of movement and catalepsy can be modeled (Scholtissen et al, 2006;Wang et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid

et al. 2017

Self Cite

View full text Add to dashboard Cite

Introduction: Motor-function modulation through Pyridine-3-carboxylic acid was assessed against. Haloperidol induced Parkinson’s disease (PD) in albino-mice. The objectives of this study were to test the effect of Haloperidol in development of PD, effectiveness of Pyridine-3-carboxylic acid in mice and evaluation of the motor-function changes in mice before and after treatment. Methods: The study was divided into 3 phases: During Phase-I (randomization), all the subjects were randomly divided into 4 groups and trained for wire-hanging, grip strength, vertical rod and swim tests for 1 week. During Phase-II (disease induction), PD was induced by intra-peritoneal (ip) administration of Haloperidol (HP) in a dose of 1 mg/kg/d for 7 days. Group-A comprised of healthy controls, Group-B (Diseased), Group-C (HP+Pyridine-3-carboxylic acid 7.15 mg/kg/d) and Group-D (HP+Pyridine-3-carboxylic acid15 mg/kg/d). Results: Pyridine-3-carboxylic acid treatment continued for 5 weeks. During Phase-III the above mention tests were performed and the effects of Pyridine-3-carboxylic acid were recorded. However, in swim test Group D is statistically insignificant as compared to Group B (p=0.284). In recent study, haloperidol is found to be effective in inducing motor function anomalies likewise in Parkinson’s disease including movement slowness, difficulties with gait and balance. Conclusion: oral administration of Pyridine-3-carboxylic acid improved Motor-function changes in diseased mice. Therefore, it is concluded that Pyridine-3-carboxylic acid may help to alleviate PD symptoms.

show abstract

“…(63,64) Lauric acid is associated with cell proliferation and survival and reduces ROS. (65,66) Diethanolamine acts as an antioxidant, (67) and pelargonic acids have also been reported to induce antioxidant activity. (68) We speculate that these changes in metabolites in GSTT1-transfected ASCs exerted a positive effect on bone differentiation.…”

Section: Discussionmentioning

confidence: 99%

GSTT1 as a Predictive Marker and Enhancer for Osteogenic Potential of Human Adipose-Derived Stromal/Stem Cells

Lee

Moon

et al. 2023

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Adipose‐derived stromal/stem cells (ASCs) have been extensively studied as cell sources for regenerative medicine for bone due to their excellent proliferative capacity and the ability to obtain a large number of cells with minimal donor morbidity. On the other hand, the differentiation potential of ASCs is generally lower than that of bone marrow‐derived stromal/stem cells and varies greatly depending on donors. In this study, we mined a marker that can predict the osteogenic potential of ASC clones and also investigated the usefulness of the molecule as the enhancer of osteogenic differentiation of ASCs as well as its mechanism of action. Through RNA‐seq gene analysis, we discovered that GSTT1 (Glutathione S‐transferase theta‐1) was the most distinguished gene marker between highly osteogenic and poorly osteogenic ASC clones. Knockdown of GSTT1 in high osteogenic ASCs by siGSTT1 treatment reduced mineralized matrix formation. On the other hand, GSTT1 overexpression by GSTT1 transfection or GSTT1 recombinant protein treatment enhanced osteogenic differentiation of low osteogenic ASCs. Metabolomic analysis confirmed significant changes of metabolites related to bone differentiation in ASCs transfected with GSTT1. A high total antioxidant capacity, low levels of cellular reactive oxygen species and increased GSH/GSSG ratios were also detected in GSTT1‐transfected ASCs. When the in vivo effect of GSTT1‐transfected ASCs on bone regeneration was investigated with segmental long‐bone defect model in rats, bone regeneration was significantly better after implantation of GSTT1‐transfected ASCs compared to that of control vector‐transfected ASCs. In conclusion, GSTT1 can be a useful marker to screen the highly osteogenic ASC clones and also a therapeutic factor to enhance the osteogenic differentiation of poorly osteogenic ASC clones.This article is protected by copyright. All rights reserved.

show abstract

Evaluation of C. cassia Effectiveness in Behavioral Modulation of Haloperidol Induced Parkinson’s Disease (Mice Model)

Cited by 9 publications

References 0 publications

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid

GSTT1 as a Predictive Marker and Enhancer for Osteogenic Potential of Human Adipose-Derived Stromal/Stem Cells

Contact Info

Product

Resources

About